Literature DB >> 8456321

Factor IX concentrates for clinical use.

A R Thompson1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8456321     DOI： 10.1055/s-2007-994003

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN： 0094-6176            Impact factor:   4.180


× No keyword cloud information.
  5 in total

1.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 3.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

5.  Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation.

Authors:  S Björkman; M Carlsson; E Berntorp
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.